Pharvaris has presented new data on deucrictibant, a novel oral bradykinin B2 receptor antagonist, at the Consortium of Independent Immunology Clinics Spring 2026 Conference. The study evaluated the safety margins of combining deucrictibant immediate-release (IR) capsules with deucrictibant extended-release (XR) tablets for treating bradykinin-mediated diseases, specifically hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The findings indicate that administering a 40 mg deucrictibant XR tablet for prophylaxis alongside one or two 20 mg deucrictibant IR capsules for breakthrough attacks is supported by adequate safety margins.

The significance of these findings lies in their potential clinical impact. The post-hoc analysis of the CHAPTER-1 study showed that the mean duration of breakthrough attacks treated with icatibant was comparable between the placebo and deucrictibant groups. This suggests that the combination of prophylactic and on-demand treatments using bradykinin B2 receptor antagonists could effectively manage HAE attacks. Dr. Peng Lu, CMO of Pharvaris, emphasized that maintaining plasma concentrations above therapeutic thresholds is crucial for preventing breakthrough attacks, and the rapid action of the IR formulation may provide a compelling treatment strategy.

The takeaway from this research is its potential to shift treatment paradigms in bradykinin-mediated angioedema. By demonstrating the safety and efficacy of a dual approach—using both prophylactic and on-demand formulations—Pharvaris may establish a new standard of care. This dual mechanism strategy could expedite drug development timelines and regulatory approvals, as the company prepares marketing authorization applications for both formulations, with pivotal data expected later this year.

Source: globenewswire.com